Treatment of a pregnant woman with an angiotensin receptor blocking (ARB) agent can result in a number of changes in the fetus termed the ARB fetopathy. The findings are similar those seen with angiotensin converting enzyme (ACE) inhibitors. Therapy with an ARB is contraindicated during pregnancy.

To read more or access our algorithms and calculators, please log in or register.